Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketsectormovers.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketSectorMovers.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX and more..
Recent SEMHF Stock Price: $51.05
Odysseas Manesiotis analyst at Berenberg Bank reiterates coverage on Siemens Healthineers AG (SEMHF) stock in the energy sector with a Buy rating and has set SEMHF's stock price target at $61.17.
TipRanks.com reports that Siemens Healthineers AG currently has 4 analysts offering 12-month price targets on SEMHF and the consensus is a Moderate Buy rating with an average stock price target of $57.86. The most recent SEMHF stock price we have is $51.05 and we are not making any SEMHF forecasts at this time.
In addition, TradingView issued a sell rating for SEMHF over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SEMHF. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SEMHF, please click here >>
AstraZeneca, AZNCF
Recent AZNCF Stock Price: $136.15
Summary: AstraZeneca PLC was incorporated in England and Wales on 17 June 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
Sachin Jain analyst at Bank of America Securities reiterates coverage on AstraZeneca (AZNCF) stock in the energy sector with a Buy rating and has set AZNCF's stock price target at $196.63.
TipRanks.com reports that AstraZeneca currently has 5 analysts offering 12-month price targets on AZNCF and the consensus is a Strong Buy rating with an average stock price target of $160.76. The most recent AZNCF stock price we have is $136.15 and we are not making any AZNCF forecasts at this time.
In addition, TradingView issued a buy rating for AZNCF over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AZNCF. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on AZNCF, please click here >>
Sanofi, SNYNF
Recent SNYNF Stock Price: $105.47
Summary: Sanofi was incorporated under the laws of France in 1994 as a société anonyme, a form of limited liability company. It is a healthcare company, engaged in the research, development, manufacture and marketing of healthcare products. Its principal activities include Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It also operates through the following platforms: Emerging Markets, Diabetes Solutions, Vaccines, Consumer Health Care (CHC), Animal Health, Genzyme, and Other Innovative Products. The Pharmaceuticals segment covers research, development, production and marketing of medicines, including activities acquired with Genzyme. Sanofi's pharmaceuticals portfolio consists of flagship products, plus prescription medicines, generic medicines, and consumer health products. This segment also includes all associates and joint ventures whose activities are related to pharmaceuticals, in particular the entities majority owned by BMS. The Vaccines segment is wholly dedicated to vaccines, including research, development, production and marketing. This segment includes Sanofi Pasteur MSD joint venture with Merck & Co., Inc. in Europe. The Animal Health segment comprises the research, development, production and marketing activities of Merial, which offers medicines and vaccines for a wide variety of animal species. Its competitors include Novo Nordisk, Merck, Eli Lilly, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, Shire, Pfizer, Biogen Idec, Teva and Merck Serono, Bayer, Roche, Johnson & Johnson, AstraZeneca, Boehringer-Ingelheim, Fresenius Medical Care, among others. The Company's products and manufacturing facilities are subject to significant government regulations and approvals.
Richard Vosser analyst at J.P. Morgan reiterates coverage on Sanofi (SNYNF) stock in the energy sector with a Buy rating and has set SNYNF's stock price target at $110.36.
TipRanks.com reports that Sanofi currently has 5 analysts offering 12-month price targets on SNYNF and the consensus is a Moderate Buy rating with an average stock price target of $112.78. The most recent SNYNF stock price we have is $105.47 and we are not making any SNYNF forecasts at this time.
In addition, TradingView issued a sell rating for SNYNF over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on SNYNF. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on SNYNF, please click here >>
Ionis Pharmaceuticals, IONS
Recent IONS Stock Price: $46.26
Summary: Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.
David Lebovitz analyst at Citi reiterates coverage on Ionis Pharmaceuticals (IONS) stock in the energy sector with a Buy rating and has set IONS's stock price target at $60.
TipRanks.com reports that Ionis Pharmaceuticals currently has 5 analysts offering 12-month price targets on IONS and the consensus is a Strong Buy rating with an average stock price target of $58.80. The most recent IONS stock price we have is $46.26 and we are not making any IONS forecasts at this time.
In addition, TradingView issued a buy rating for IONS over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IONS. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on IONS, please click here >>
The editors at marketsectormovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketSectorMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to MarketSectorMovers.com.
==============================================================================
